December 2023

The therapy sustained IDFS benefit compared with ET alone.

The results confirm tebentafusp as a standard of care.

The results support perioperative nivolumab as a potential new treatment option.

Treatment options can be limited for this patient population.

There is a prognostic impact of clinical and immunohistochemistry markers.

Although treatment is effective, AEs remain difficult for patients.

Hospice care is only a part of palliative care services.

AFPs limit access to provider-prescribed specialty medications.

Axitinib, cabozantinib, and lenvatinib are first-line treatment options.

An overview of how gene therapy has evolved since its inception, current applications, and emerging challenges.

Seven new agents have received FDA approval since October 2022.

Exclusions of medication are often focused on high-cost specialty formularies, resulting in fewer options for patients who need them.